Dr. Anthony D Elias, M.D.
Claim this profileUniversity of Colorado
Studies Breast Cancer
Studies Soft Tissue Sarcoma
12 reported clinical trials
32 drugs studied
Area of expertise
1Breast Cancer
Stage IV
ER positive
HER2 negative
2Soft Tissue Sarcoma
Stage IV
esophageal carcinoma
gastric carcinoma
Affiliated Hospitals
Clinical Trials Anthony D Elias, M.D. is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Personalized Adaptive Novel Agents
for Breast Cancer
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Recruiting1 award Phase 216 criteria
More about Anthony D Elias, M.D.
Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Anthony D Elias, M.D. has experience with
- Paclitaxel
- Enzalutamide
- Fulvestrant
- CAB-ROR2-ADC
- PD-1 Inhibitor
- Nivolumab
Breakdown of trials Anthony D Elias, M.D. has run
Breast Cancer
Soft Tissue Sarcoma
Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anthony D Elias, M.D. specialize in?
Anthony D Elias, M.D. focuses on Breast Cancer and Soft Tissue Sarcoma. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER positive.
Is Anthony D Elias, M.D. currently recruiting for clinical trials?
Yes, Anthony D Elias, M.D. is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Anthony D Elias, M.D. has studied deeply?
Yes, Anthony D Elias, M.D. has studied treatments such as Paclitaxel, Enzalutamide, Fulvestrant.
What is the best way to schedule an appointment with Anthony D Elias, M.D.?
Apply for one of the trials that Anthony D Elias, M.D. is conducting.
What is the office address of Anthony D Elias, M.D.?
The office of Anthony D Elias, M.D. is located at: University of Colorado, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.